Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.

ABSTRACT:

Background

Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood.

Methods

The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early

SUBMITTER: Hutchison RM 

PROVIDER: S-EPMC8609885 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature